Piramal Pharma Q1 revenue rose mid-to-high teens across all three segments, with EBITDA margin widening. The CDMO, complex hospital generics, and consumer health units each contributed to the result.
Alpha Score of 62 reflects moderate overall profile with strong momentum, moderate value, moderate quality, moderate sentiment.
Piramal Pharma Ltd. (NSE: PPLPHARMA) reported a strong start to its fiscal year, with all three businesses delivering mid-to-high teens revenue growth in the quarter ended June 30, accompanied by meaningful EBITDA margin expansion. The company's contract development and manufacturing segment, complex hospital generics unit, and consumer health division each contributed to the result, Chairperson Nandini Piramal said in a statement Monday.
Revenue from the CDMO business rose on broad-based growth across India and overseas sites, supported by an expanded commercial team, healthy request-for-proposal activity, and order inflows. The complex hospital generics segment maintained its lead in key therapies, gained traction in ex-U.S. inhalation anesthesia markets, and continued progress on the integration of Kenalog, the branded corticosteroid injection acquired in a prior period. The consumer health business posted what the company called another quarter of robust growth, driven by its Power Brands, e-commerce, wider distribution, premiumization, and disciplined brand investments.
“We have started FY27 on a strong note, with all three businesses delivering mid-to-high teens revenue growth alongside meaningful EBITDA margin expansion,” Piramal said.
Piramal Pharma offers a portfolio of differentiated products and services through 17 development and manufacturing facilities globally and a distribution network covering more than 100 countries. The company has three operating units: Piramal Pharma Solutions, an integrated contract development and manufacturing organization; Piramal Critical Care, a complex hospital generics business; and Piramal Consumer Healthcare, which sells over-the-counter consumer and wellness products. One of its associate companies, Abbvie Therapeutics India Private Ltd., a joint venture between AbbVie and Piramal, has become a leader in the ophthalmology therapy area in the Indian pharmaceutical market. Piramal also holds a minority investment in Yapan Bio Private Ltd., which operates in the biologics and vaccine segments.
The quarter's results included exceptional items. In the year-ago period, the company recorded one-time insolvency proceeds from a claim filed against a third-party supplier of the complex hospital generics business, with the National Company Law Tribunal in November 2023. The current period did not include a comparable item, the company said.
Piramal said she looks forward to sustained revenue growth and EBITDA expansion through the fiscal year, while staying agile amid a dynamic external environment. The company will host a conference call for investors and analysts on July 30 at 9:30 a.m. IST.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.